Kornimate/medical-research-clean huggingface dataset:
evaluation of an intervention to increase colorectal cancer screening in primary care clinics

Conditions: Colorectal Cancer

Summary: this study is a three-arm randomized controlled trial to implement and evaluate the relative effects of: 1) clinic-focused intervention; 2) combined patient- and clinic-focused intervention, and 3) usual care on the provision of colorectal cancer (crc) screening in primary care clinics. the study will also examine the relative effects of the intervention conditions on secondary behavioral outcomes (e.g., clinician-patient discussions about crc screening) and on intermediate outcome measures of attitudes, beliefs, opinions, and social influence surrounding crc screening among patients, clinicians, and clinical staff. the target population includes average-risk patients aged 50-75 years, clinicians, and clinical staff within the primary care setting. the intervention will be implemented within primary care clinics in two managed care organizations (mcos). the intervention targets the following crc screening modalities: fecal occult blood test (fobt), flexible sigmoidoscopy, colonoscopy, and double contrast barium enema.


Eligibility criteria:
inclusion criteria: inclusion criteria for the patient-focused intervention * average risk * male or female * 50-75 years * scheduled for non-acute ambulatory care visit at one of the study sites * due for crc screening including no record of fobt in the past year, no record of flexible sigmoidoscopy in the past 5 years, no record of colonoscopy in the past 10 years, and no record of double contrast barium enema in the past 5 years inclusion criteria for the clinic-focused intervention * primary care clinicians, to include the following specialties: family practice/general practice physicians, general internal medicine physicians, nurse practitioners in family/general practice, physician assistants who conduct non-acute ambulatory medical exams in study clinics * primary care clinical staff, to include nurses, medical assistants, and appointment schedulers exclusion criteria (patients): * prior diagnosis of crc * prior diagnosis of colorectal polyps * prior diagnosis of ulcerative colitis * prior diagnosis of crohn's disease * prior diagnosis of hereditary nonpolyposis or polyposis * medical records contain an international classification of diseases (icd-9) code for family history of crc * younger than 50 years of age * older than 80 years of age.

Keywords: cancer colorectal cancer patient education physician education
topical ph-10 aqueous hydrogel and photodynamic therapy for psoriasis

Conditions: Plaque Psoriasis

Summary: this is an open label, single center, controlled study with each subject's two treatment plaque areas assigned by the investigator 1:1 to (a) ph-10 with ambient light exposure and (b) ph-10 with 544 nm led light illumination at 10 j/cm2. a third plaque area will receive no treatment and serve as a control. subjects with at least three distinct, stable study plaque areas will receive the experimental therapy to two treatment plaque areas twice a week (2-5 days apart) for the lesser of 12 weeks or until remission is observed in the treatment plaque areas. if remission is observed in a treatment plaque area then treatment of that area will be discontinued and the area assessed weekly. a third plaque area (control plaque area) will receive no drug or light treatment and serve as an internal control. primary efficacy will be assessed 12 weeks after initial ph-10 treatment. subjects will be followed for a total of 16 weeks to allow assessment of durability of response of treated lesions and comprehensive follow-up of adverse events.


Eligibility criteria:
inclusion criteria: * stable, moderate to severe plaque psoriasis in at least three distinct plaque areas, each separated by at least a 2.5-cm band of normal skin. study plaque areas, each covering a contiguous area up to 15 x 35 cm in size, should have a minimum plaque size of 2 cm2. all study plaque areas must be on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous sites). * fitzpatrick skin type i-vi. * ability to understand and sign the informed consent document. exclusion criteria: * female subjects of childbearing potential who are pregnant, attempting to conceive, or nursing an infant. * subjects who have received puva or uvb light therapy or systemic antipsoriatic therapy within 4 weeks of study treatment (two weeks for methotrexate). * subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin, or vitamin d analogs) to the study plaque areas within 2 weeks of study treatment. * subjects who have received any photosensitizing or phototoxic drug within 4 weeks of study treatment. * subjects who have received any approved biologic drug therapy for psoriasis within 3 months or 5 half-lives of study treatment. * subjects who have participated in a clinical research study within 4 weeks of study treatment. * subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum. * subjects with clinical conditions that, in the opinion of the principal investigator, may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
the 28 day challenge

Conditions: Depression; Anxiety; Stress; Hope

Summary: the purpose of this study is to determine how a 28 day challenge influences mental health and well-being. this is a blinded study. participants both with and without depression and anxiety, will be included. a moderation analysis will be performed to see whether changes in depression after the intervention are a function of baseline depression and anxiety levels.


Eligibility criteria:
inclusion criteria: * english fluency exclusion criteria: * severe hearing impairment
cellular immunotherapy for immune tolerance in past recipients of hla zero-mismatch, living donor kidney transplants

Conditions: Kidney Transplant Rejection

Summary: the primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with mdr-103 for induction of functional immune tolerance in past recipients of human leukocyte antigen (hla)-matched, living donor kidney transplants.

currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. these medications carry substantial side effects. in addition, these medicines often do not completely control damage to the kidney from the recipients' immune system, ultimately causing the kidney to fail. medeor therapeutics is developing a novel cell-based therapy to reprogram the past recipients' immune system to accept the transplanted kidney without the concurrent need for long term use of immunosuppressive drugs. the purpose of the current phase 2 study is to demonstrate the efficacy and safety of mdr-103 for the induction of transplant immune tolerance in a prospective, multicenter clinical trial. mdr-103 is intended to induce mixed lymphohematopoietic chimerism and donor specific immune tolerance in order to preserve transplant kidney function, avert transplant kidney rejection, and eliminate the cumulative and serious side effects associated with immunosuppressive drugs.

Eligibility criteria:
inclusion criteria: recipient inclusion criteria: * past recipient of a first kidney allograft from an hla-matched, living related donor * age ≥18 and ≤70 years * single solid organ recipient (kidney only) * abo compatibility with donor donor inclusion criteria: * hla-matched first degree (parent, child or sibling) or second-degree (child of a sibling, half sibling) relative of the prospective recipient participant * age ≥18 and ≤70 years * past living related kidney donor, and capable of undergoing g-csf mobilization and apheresis of hematopoietic cells exclusion criteria: recipient exclusion criteria: * underlying kidney disease with a high risk of disease recurrence in the transplanted kidney * baseline positive donor-specific anti-hla antibody testing * is taking immunosuppressive therapy * evidence of prior hepatitis b (hbv) or hepatitis c (hcv) donor exclusion criteria: * history of autoimmune disorders * history of type 1 or type 2 diabetes mellitus * tests confirmed positive for human immunodeficiency virus (hiv), hbv, hcv * history of infection with zika virus

Keywords: kidney transplant kidney failure anti-rejection therapy living donor hla-matched hematopoietic stem cells (hsc) cd34+ cd3+ t cells cellular therapy immunotherapy immunosuppression
effect of soleus pushup exercise in type 2 diabetes patients

Conditions: Diabetes Mellitus, Type 2

Summary: the aim of this research is to compare the immediate effects of one hour soleus pushup exercise and treadmill walk in type 2 diabetic population on blood glucose level. randomized controlled trials done at railway general hospital and diabetic centers of rawalpindi and islamabad.. the sample size was 66. the subjects were divided in two groups, 33 subjects in soleus pushup exercise group and 33 subjects in treadmill walk group. study duration was of 6 months. sampling technique applied was non probability convenience sampling technique. only 40-60 years diabetic people with clinically diagnosed type 2 diabetes for upto 10 years were included. tools used in the study are glucometer

diabetes is on the rise worldwide, with a global prevalence in adults in 2021 being 537 million adults (20-79 years) living with diabetes -one in ten. this number is predicted to rise to 643 million by 2030 and 783 million by 2045. over 3 in 4 adults with diabetes live in low- and middle-income countries. although physical activity (pa) is a key element in the prevention and management of type 2 diabetes. structured interventions combining physical activity and modest weight loss have been shown to lower type 2 diabetes risk by up to 58% in high-risk populations. the increase in t2dm prevalence can only partly be attributed to the increasing prevalence of obesity and a sedentary lifestyle. the exercise recommendations for individuals with type 2 diabetes are similar as for the general population, suggesting a minimum of 150 min of moderate-vigorous-intensity aerobic exercise each week. however, the general population doesn't adhere to these guidelines. the goal of treatment in type 2 diabetes is to achieve and maintain optimal bg, lipid, and blood pressure (bp) levels to prevent or delay chronic complications of diabetes. a fundamental principle in exercise physiology is that a small muscle mass working in isolation can achieve a higher local oxygen consumption (vo2/min per kg) than when recruiting a large muscle mass. the soleus (1% body mass) has a highly pennated architecture favoring greater amounts of muscular work during plantarflexion. it has an exceptionally high physiological cross-sectional area (3-8 times more than most of the 20 other limb muscles studied).

Eligibility criteria:
inclusion criteria: * • both male and female individuals * individuals with age between 40 to 60 years * individuals with clinically diagnosed diabetes type 2 up to 10 years * individuals not engaged in a structured walking/exercise program * 2 hours post meal with glucose ranging upto 200. exclusion criteria: * • no recent or planned changes in diet, physical activity, or medications. * participants diagnosed with pre-diabetes, gestational diabetes, or type 1 diabetes

Keywords: diabetes mellitus, type 2 soleus push up treadmill walk blood glucose
health impacts of street vended fruits

Conditions: Gastrointestinal Diseases; Foodborne Diseases; Microbial Contamination; Street Vended Foods; S. Aureus; Escherichia Coli; Total Viable Count

Summary: this study will employ a randomized controlled intervention design to evaluate the health impacts of consuming fresh-cut street-vended fruits, focusing on microbial contamination and gastrointestinal (gi) symptoms. a total of 300 participants will be recruited and divided into treatment (consuming guava, pineapple, or watermelon) and control groups (no fruit consumption). fruit samples will be analyzed for microbial contamination, including s. aureus and e. coli, using standard microbiological and molecular techniques. data on gi symptoms will be collected through questionnaires and analyzed using statistical methods, such as chi-square tests, kaplan-meier survival analysis, and cox proportional hazards regression. spearman correlation will identify associations between bacterial presence and specific symptoms. ethical approval will be obtained, and participant safety will be prioritized. analytical tools, including ibm spss, rstudio, and pycharm, will be utilized for the analyses.


Eligibility criteria:
inclusion criteria: * individuals aged 18-60 years. * residents of mymensingh district, bangladesh. * willing to consume fresh-cut street-vended fruits (guava, pineapple, or watermelon) for five consecutive days. * individuals with a self-reported history of gastric acidity issues (for the gastric acidity arms). * individuals with no history of gastric acidity (for the non-gastric acidity arms). * participants who have not taken antibiotics, proton pump inhibitors (ppis), or antacids in the last two weeks. * willing to provide detailed information on their dietary habits and gastrointestinal symptoms through surveys/questionnaires. * participants who provide informed consent for participation. exclusion criteria: * individuals under 18 years or over 60 years. * pregnant or lactating women. * those with a diagnosed gastrointestinal disorder (e.g., peptic ulcer disease, irritable bowel syndrome, crohn's disease). * individuals with a history of chronic infections or immune-compromising conditions (e.g., hiv/aids, cancer, diabetes). * participants who have taken antibiotics, ppis, or antacids within the last two weeks. * individuals with known allergies to guava, pineapple, or watermelon. * those who refuse to consume fresh-cut fruits from street vendors. * participants who do not provide informed consent or are unable to complete the study period.

Keywords: gastrointestinal symptoms food borne illness food safety food borne infection food poisoning s. aureus e. coli bacterial contamination bacterial load
coa-aptic clinician concept elicitation study

Conditions: Pain Measurement

Summary: this is a concept elicitation study to identify important aspects of acute pain assessment, treatment, and response to treatment in infants and young children, age 0 to 3 years old, from a clinician's perspective.

the purpose of this study is to identify important endpoints and outcomes for use in pediatric trials of acute pain therapeutics in children who are 0 to \<3 years of age from a clinician's perspective. to identify these endpoints and outcomes the investigators will conduct remote qualitative concept elicitation interviews with 27 clinicians who treat pediatric patients. these interviews will include verbal consent to participate, a demographics questionnaire, and a semi-structured interview which will last approximately one hour. interview questions will address the participant's professional experience recognizing and managing pain in children between 0 and 3 years of age. interviews will be audio recorded and transcribed with the participant's permission. transcripts and notes will be coded and analyzed. this is a minimal risk study; the investigators are only using standard interview procedures and are not collecting any protected health information from participants. while the investigators do not believe that any information collected would jeopardize the personal or professional standing of participants, all information will be kept strictly confidential per good clinical practice guidelines.

Eligibility criteria:
inclusion criteria: 1. is a practicing clinician in a clinical care environment 2. cares for pediatric patients \>50% of their time 3. treats or works with pediatric patients who are between 0 and \<3 years of age and being treated for acute pain 4. holds one of the following titles/positions 1. physician 2. clinical pharmacist (pharmd) 3. nurse practitioner 4. physician assistant 5. nurse (with a bsn/rn or higher) 5. is over the age of 18 years 6. can speak and understand english 7. is capable of giving informed verbal consent exclusion criteria: 1. lack of access to a telephone for interview
menopause transition, sex hormone deficiency and autonomic and vascular function

Conditions: Menopause

Summary: this is a longitudinal study to determine the influence of the menopause transition on autonomic and vascular function. pi keller-ross has published data demonstrating that postmenopausal females have greater sympathetic neural reactivity during a stressor compared with age-matched males and younger females and males. a paucity of literature exists, however, on the role of the menopause transition in autonomic function because the majority of experimental studies on menopause physiology are cross-sectional and/or focused on older, postmenopausal females . the influence of age on htn is robust, whereas the effects of menopause are still unclear. preliminary data demonstrate a clear association between age and sympathetic activity in females; how the transition through menopause influences these relations, however, remains unknown. the study will enroll 80 midlife (45-55 years of age) females to measure longitudinally the trajectory of autonomic and vascular function during the transition through menopause. the study hypothesizes that through the menopause transition, an increase in sympathetic activity and an impaired baroreflex sensitivity and endothelial function will emerge.


Eligibility criteria:
inclusion criteria: * female * age 45-55 years * premenopausal * not using any medications determined to affect autonomic function * eumenorrheic * not planning to become pregnant for the duration of participation in the study * english-speaking, literate, willing and able to provide informed consent. exclusion criteria: * diabetes * pregnant or breastfeeding * cardiac or pulmonary disorders * severe obesity (body mass index \[bmi\] ≥ 40 kg/m 2 ) * hypertension * obstructive sleep apnea * current use of heart or blood pressure medications, current use of hormonal contraceptives or other forms of exogenous sex hormones * report of nicotine/tobacco use in the last six months, report of current alcohol abuse, * history of treatment with chemotherapy/radiation * coagulopathy disorders and/or use of anticoagulant medications, and current use of anxiolytics and/or antidepressants.

Keywords: blood pressure perimenopause vascular
a study on the immune-response to covid-19 vaccination in cancer patients - the iosi-covid-19-001 study

Conditions: Covid19; Cancer

Summary: this is a single centre prospective observational study to assess the immune response to sars-cov-2 vaccines in cancer patients receiving active treatment or in follow-up at the iosi and in non-cancer patients (age and gender matched).

this study will be conducted on 7 cohorts of cancer patients and 1 cohort of non-cancer subjects (age and gender matched) with a sample size of 30 patients in each cohort: all enrolled patients will be asked to provide blood samples (2 x 10cc heparin tubes) at the following time points: * baseline: before the administration of the first dose of the sars-cov-2 vaccine (within 4 weeks). * before the second dose of the sars-cov-2 vaccine (within 7 days). * follow-up: after 3, 6, 9 and 12 months after the second dose of the sars-cov-2 vaccine. a +/- 14 days window is allowed at each follow-up time point.

Eligibility criteria:
inclusion criteria: * male of female age at least 18 years * patients with a diagnosis of malignancy (solid tumors or hematological malignancies) according to the defined cohorts. only for cohorts 1-7 * eastern cooperative oncology group (ecog) performance status 0-2 * absence of known immune deficiency (other than cancer for cohorts 1-7) * ability to understand the patient information and study consent. signed and dated written informed consent must be available before performing any study-related procedure * willing and able to comply with the study procedures. * willing to receive an mrna anti-sars-cov-2 vaccine.
rotateq® and meningococcus c vaccine in healthy infants (v260-016)

Conditions: Meningitis, Meningococcal; Rotavirus Infections

Summary: primary objective: to check if rotateq® can be administered concomitantly with meningococcal group c vaccine without impairing the efficacy of mcc vaccine. the hypothesis tested is that the seroprotection rate for mmc at 28 days after the second mcc vaccination with concomitant administration of rotateq® is non-inferior to that without non-concomitant (sequential) administration of rotateq®.


Eligibility criteria:
inclusion criteria: * healthy infants, aged from 6 weeks through full 7 weeks, * consent form signed by at least one parent or by the legal representative properly informed about the study, * parent(s) / legal representative able to understand the protocol requirements and to fill in the diary card. exclusion criteria: * history of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery, * congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, * known or suspected impairment of immunological function, * known hypersensitivity to any component of rotateq® (e.g. sucrose) or of neisvac-c® (including tetanus toxoid), * prior administration of any rotavirus vaccine, * prior administration of any vaccine within the 28 days prior to randomisation, * fever (rectal temperature ≥38.1°c) and/or acute diarrhoea and/or vomiting at randomisation, * history of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive, * any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, * clinical evidence of active gastrointestinal illness, * receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. note: infants on inhaled and/or topical steroids may participate in the study, * infants residing in a household with an immunocompromised person, * prior receipt of a blood transfusion or blood products, including immunoglobulins.

Keywords: prevention of gastroenteritis due to rotavirus infection. and prevention of invasive disease caused by neisseria meningitidis serogroup c.